Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results

Press Release – No. 8 / 2026

Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results

Copenhagen, Denmark and Boston, Massachusetts, April 30, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that it will host a conference call on May 7, 2026, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter / first three months of 2026.

Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The presentation will be followed by a Q&A session.

To receive telephone dial-in information and a unique personal access PIN, please register at Conference Registration. The live listen-only audio webcast of the call and accompanying slides presentation will be accessible at Zealand Pharma results for Q1 2026. Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on the Investor section of Zealand Pharma’s website at https://www.zealandpharma.com/events/.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.

To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.

Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.

Contacts
Eric Rojas (Investors)
Vice President, Head of Investor Relations
[email protected]

Adam Lange (Investors)
Vice President, Investor Relations
[email protected]

Neshat Ahmadi (Investors)
Investor Relations Manager
[email protected]

Rachel James-Owens (Media)
Vice President, Corporate Communications & Media Relations
Zealand Pharma
Email: [email protected]

Andreas Hylleberg (Media)
Director, External Communications
Zealand Pharma
Email: [email protected]

Amber Fennell, Jessica Hodgson, Sean Leous (Media)
ICR Healthcare
Email: [email protected]
+44 (0) 7739 658 783

You May Also Be Interested In

• Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
• MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
• MP Materials seen largely insulated after China export-control move